A Multiple Ascending Dose Study of R4733 in Patients With Advanced Solid Tumors.
NCT00532090
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
110
Enrollment
INDUSTRY
Sponsor class
Conditions
Neoplasms
Interventions
DRUG:
RG4733
DRUG:
RG4733
DRUG:
RG4733
Sponsor
Hoffmann-La Roche